Skyrizi®(Risankizumab)获得加拿大药品局对溃疡性结肠炎的积极报销推荐,艾伯维公司与泛加拿大药品联盟签署谅解备忘录
Skyrizi®(Risankizumab)获得加拿大药品局对溃疡性结肠炎的积极报销推荐,艾伯维公司与泛加拿大药品联盟签署谅解备忘录
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.